Wells Fargo Initiates Coverage On Kiniksa Pharmaceuticals with Overweight Rating, Announces Price Target of $34
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Eva Fortea Verdejo has initiated coverage on Kiniksa Pharmaceuticals (KNSA) with an Overweight rating and set a price target of $34.
May 03, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has initiated coverage on Kiniksa Pharmaceuticals with an Overweight rating and a price target of $34.
The initiation of coverage by a major financial institution like Wells Fargo, especially with an Overweight rating and a significant price target of $34, is likely to generate positive sentiment among investors. This could lead to increased investor interest and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100